tailieunhanh - Bortezomib prevents cytarabine resistance in MCL, which is characterized by downregulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. | Bortezomib prevents cytarabine resistance in MCL which is characterized by downregulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN